Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran
This study showed that rivaroxaban plus aspirin is a cost-effective alternative in PAD and total of CAD and PAD patients. In CAD patients, rivaroxaban plus aspirin and rivaroxaban alone were not cost-effective.
Authors
- Zahra Goudarzi (ORCID: https://orcid.org/0000-0002-7096-5276)
- Ahmad Gholami (ORCID: https://orcid.org/0000-0003-1851-159X)
- Khosro Keshavarz (ORCID: https://orcid.org/0000-0002-5778-5502)
- Zhila Najafpour (ORCID: https://orcid.org/0000-0003-0258-8015)
- Mohammad Mahdi Mojahedian (ORCID: https://orcid.org/0000-0002-8851-2195)
- Mohammad Mehdi Babayi
Institutions
- Ahvaz Jundishapur University of Medical Sciences (IR)
- Iran University of Medical Sciences (IR)
- Shiraz University of Medical Sciences (IR)
- Biotechnology Research Center (IR)
- Tehran University of Medical Sciences (IR)
Publication Details
- Journal
- BMC Health Services Research
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1186/s12913-025-12431-3
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00